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The purpose was to compare the short-term cost-effectiveness of intensive vs conventional education and supervision 
for the self-management of mild asthmatic patients. Consecutive newly diagnosed asthmatic patients (n= 162) were 
randomized into an intervention group (IG) and a control group (CG) with 1 yr of treatment and follow-up. 
Intensive education was given to 77 patients at visits every third month in the outpatient clinic. Eighty CG patients 
received conventional education and advice at the baseline visit only. All patients received similar inhaled 
anti-inflammatory treatment. 
At baseline and at 12 months standard clinical lung functions and health-related quality of life (HRQOL) were 
measured, the latter by the disease-specific St George’s Respiratory Questionnaire and the generic 15D. Further- 
more, the use of extra health care services, medication and sickness days were recorded. The IG experienced a 
significant improvement in all clinical and HRQOL outcome variables. The same applied to the CG except 
spirometric values. The groups differed significantly only in terms of FEV, (P<O.O5) in favour of the IG. There was 
a significant difference between the groups in extra costs. The mean cost was FIM 2351 per patient (&294 sterling) 
in the CG and FIM 2757 per patient (&345) in the IG, of which the intervention cost was FIM 1978 per patient 
(f247). In 1 yr follow-up the intensive education programme did not prove to be cost effective but was dominated 
by the conventional one regardless of what effectiveness measure was used. Also, a purely monetary cost-benefit 
calculation showed that the intervention resulted in a negative net benefit (loss) of FIM 406 per patient (&51). A 
longer follow-up may be needed before definitive conclusions about the cost-effectiveness of this kind of intervention 
can be drawn. 
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Introduction 
The total social costs of asthma are rising in Finland as the 
number of asthmatic patients increases. Most patients in 
Finland (60%) have a mild form of the disease and account 
for approximately 20% of total social costs, mainly as direct 
costs. About 60% of total costs are attributed to those 
suffering from severe or moderate asthma, the most signifi- 
cant costs being indirect ones. For better treatment results 
in the long run, and consequently fewer severe asthma cases 
and thus decreased social costs, patients today are encour- 
aged from the onset to assume an active responsibility for 
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managing their disease. Therefore they should be familiar 
with the principles of treatment and be guided in 
self-management (1). 
Patient education and self-management have been 
reported to decrease asthma morbidity (2-7) or to be cost 
effective in many studies among chronic, mostly moderate 
or severe asthmatics (8-14). However, these evaluations 
have been based on selected outcomes and costs, some 
studies have been uncontrolled or the treatment was based 
on special trial medication. 
The aim of this study was to compare an intensive patient 
education and supervision programme for self-management 
vs a conventional approach among newly diagnosed 
asthmatic patients in terms of cost-benefit and cost- 
effectiveness. The study was based on a randomized clinical 
trial with treatment based on usual clinical practice in both 
groups. Evaluation was made after the first treatment year. 
All customary clinical outcome measurements were used 
with health-related quality-of-life (HRQOL) instruments. 
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TABLE 1. Baseline characteristics of the patients (standard 
deviations in parentheses) 
Intervention Control 
(n=80) (n=82) 
Sex (m, 0 
Mean age (years) (range) 
Atopy* 
Current smokers 
Forced vital capacity (FVC) 
(% of predicted) 
Forced expiratory volume 
in one second 
(FEV,) (o/o of predicted) 
FEVJFVC 
Peak expiratory flow 
(PEF) (‘XI of predicted) 
15D score 
SGRQ total score 
Treatment: 
Inhaled corticosteroid 
Nedocromil 
25, 55 35, 47 
43.1 (18-76) 44.2 (19976) 
52 39 
19 16 
95.1 (12.5) 92.5 (14.8) 
86.1 (14.0) 
90.0 (10.0) 
84.3 (11.4) 83.4 (13.5) 
0.89 (0.10) 0.89 (0.10) 
27.0 (14.6) 27.7 (15.6) 
75 
5 
82.8 (14.8) 
89.1 (9.7) 
77 
5 
*At least one positive skin prick test reaction to common 
allergens. 
Both extra direct and indirect costs were calculated for 
economic analysis. 
Methods 
PATIENTS 
Between September 1991 and February 1993, 162 consecu- 
tive new asthmatic patients were diagnosed according to the 
criteria of the American Thoracic Society (15) in South 
Karelia Central Hospital. They all showed a reversible 
airways obstruction with an increase of at least 15% in the 
forced expiratory volume in 1 s (FEV,) or in peak expira- 
tory flow (PEF) in response to bronchodilators. The 
patients had not previously used inhaled anti-inflammatory 
asthma medication. 
At the time of diagnosis, the patients were informed 
about the study. One month later, they visited the attending 
chest physician for conventional guidance in treatment and 
self-management. After that, they were randomized by 
using a computerized list with consecutive numbers. The 
nurse on duty then made the next appointments according 
to the study plan. 
The intervention group (IG) consisted of 80 patients 
and the control group (CG) of 82 patients. Patient 
characteristics at baseline are given in Table 1. 
The routine treatment programme was followed. The 
principle is to use higher doses of inhaled corticosteroid or 
nedocromil during the first 2 months and then to decrease 
doses according to PEF measures. Most patients had 
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inhaled corticosteroid from the beginning. Ten patients 
started with nedocromil. The medication was prescribed for 
1 yr at the randomization visit. The pharmacies delivered 
the drugs for 3 months use at a time. The prescribed mean 
maintenance doses were 1.01 mg beclomethasone (Bcl), 
0.97 mg budesonide (B) and 11 mg nedocromil (N) in the 
IG and 1.03 mg Bcl, 0.97 mg B and 10 mg N in the CG. 
Inhaled bronchodilating medication was used according to 
need. Corticosteroid tablets were not prescribed in advance 
during the first year of treatment. The compliance was 
checked at 1 yr on the basis of oral information given by the 
patient. 
The study plan was approved by the Hospital Ethical 
Committee and the informed consent was obtained from all 
patients. 
THE EDUCATION PROGRAMME 
The conventional patient education programme com- 
menced at the visit for diagnosis and consisted of basic 
education for the use of inhaled drugs, peak expiratory flow 
(PEF) follow-up and the principles of treatment. The 
programme was administered. by two qualified respiratory 
nurses specially trained for that purpose. At the random- 
ization visit the patient was educated in guided self- 
management and a videotape concerning asthma was 
shown to both groups. 
The education continued in the IG at the visits to the 
clinic every third month and was given alternately by the 
nurse or attending chest physician. The time used for each 
visit was 30 min. The visit to the chest physician after 
6 months was for supervising education and treatment, but 
no changes were made in medication at this visit. The 
first visit, after 3 months of treatment, was conducted by 
the same nurse who began the education. The self- 
management plan, use of drugs and PEF follow-ups were 
checked, misuse habits were corrected and treatment prin- 
ciples repeated. Between 6 and 9 months all patients 
participated in a 2 h education programme, given by a 
qualified physiotherapist and two qualified nurses, one 
of whom specialized in social affairs and the other in 
rehabilitation. The course was attended by two or three 
patients at a time. 
The CG received conventional education at baseline 
only. They were advised to adjust their medication accord- 
ing to the self-management plan and to contact their 
health centre whenever they had symptoms or other 
problems. Their next planned visit was 11 months after 
randomization. 
SELF-MANAGEMENT PLAN 
A peak-flow meter and a diary were given to both groups 
for the first year. Patients were asked to follow their PEF 
values whenever symptoms appeared and at least for 2 
weeks every third month, recording the values in the diary. 
This plan is approximately the same as the one later stated 
in the Finnish asthma programme (1). 
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TABLE 2. The mean values of lung functions (as a percentage from predicted) at baseline and at 1 yr 
follow-up in the intervention and control groups (95% CI in parentheses) 
Intervention group Control group 
At baseline At 1 yr At baseline At 1 yr 
Difference between 
the groups at 1 yr, 
P values 
FVC 94.7 99.8*** 92.5 94.7 
(91.8-97.6) (966102.9) (89.2-95.6) (91.3- 98.1) 
FEV, 85.7 92.3*** 82.8 84.7 
(82.5-88.9) (88.5-96.1) (79.5586.1) (81.0- 88.4) 
FEV% 90.0 91.9” 89.1 88.9 
(87.8-92.2) (89.7-94.2) (86.9-91.2) (866 91.2) 
PEF 84.2 91.6*** 83.4 87.1** 
(81.6-86.7) (88.7794.4) (80.4-86.4) (83.8- 90.5) 
PD,, (mg ml- ‘) 0.10 0.31*** 0.10 0.25 
geometric mean (0.08-O. 13) (0.24-0.41) (0.08-O. 13) (0.18-0.34) 
As dose steps 0.54 1.41*** 0.58 1.23*** 
(0.36-0.72) (1.19-1.63) (0.40&0,76) (1.06 1.47) 
0.08 
0.02 
0.18 
0.17 
0.56 
0.28 
Significance of the difference between baseline and one year, paired samples t test: ***P<O.OOl 
**p<o.o1 *p<o.o5. 
FVC, forced vital capacity; FEV,, forced expiratory volume in 1 s; PD,,, airway responsiveness, 
provocative dose mg of histamine. 
The plan was written in the diary as follows: 
l If the PEF value falls below 80-85% of the predicted or 
of the individual’s optimal value, the inhaled cortico- 
steroid or nedocromil dosage should be doubled until the 
PEF level is normal and stabilized. 
l If the PEF value falls below 70%, double the dosage and 
contact your doctor. 
l If the PEF value falls below 50%, go to the emergency 
department. 
l Use your inhaled bronchodilating drug whenever you 
have symptoms. 
Both groups recorded the use of extra health care services, 
extra medication and sickness days in the diary. 
OUTCOME MEASUREMENTS 
Clinical measurements at baseline and at 12 months were 
performed at least 12 h after the last use of bronchodilating 
drugs. A flow volume spirometer, Medikro 101 (Medikro 
Ltd, Kuopio, Finland) calibrated daily according to stan- 
dard quality criteria, was used for measuring forced vital 
capacity (FVC) and forced expiratory volume in 1 s 
(FEV,). FEV,/FVC=FEV% was then calculated. PEF was 
measured by Wright’s peak-flow meter during the visit 
to the clinic. The Finnish normal spirometric (16) and 
Nunn’s PEF (17) values were used and adjusted for age, 
gender and height. The results are given as a percentage 
from normal values (Table 2). Airway responsiveness 
was measured by the provocative dose of histamine 
required to cause a 15% fall in FEV, (PD,,) (18). 
The results are also expressed as dose steps, e.g. step 0 is 
PD,, co.11 mg; step 1 is PD,,=O.ll-0.4 mg, step 2 is 
PD,,=04l1.6 mg and step 3 is PD,, ~1.6 mg. Changes 
in airway responsiveness were expressed as the geometric 
mean mg/ml of histamine and as the mean change in dose 
steps of PD,, (Table 2). 
HRQOL MEASUREMENTS 
The 15D is a generic HRQOL instrument with 15 dimen- 
sions: moving, seeing, hearing, breathing, sleeping, eating, 
communicating, eliminating, working, social participation, 
mental functioning, pain-ache, depression, distress and 
perceived health. Each dimension is divided into four or five 
ordinal levels. Individuals choose from each dimension the 
level that best describes his or her health status at that 
moment. The instrument also includes a system of prefer- 
ence weights, elicited in a population survey, by which the 
responses to the dimensions are converted into a single- 
index score (15D score) on a O-l scale (1 is full HRQOL, 0 
being death) (19,20). Among the Finnish population 
the average 15D score in age group 3544 years is 0.95 and 
in age group 65-75 years 0.86 (21). The 15D can be 
used both as a single-index number measure and as a 
profile measure. 
The St George’s Respiratory Questionnaire (SGRQ) 
measures the experience of well-being and the impairment 
of quality of life caused by a respiratory disease and is thus 
disease specific. Seventy-six items are divided int,o three 
domains-symptoms, activity and impact on daily life - 
from which the total score is calculated (22-24). Zero 
represents the best possible health situation and 100 the 
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worst. The patients completed the questionnaires in 
hospital during their visits. 
COSTS 
Costs are based on the actual cost in South Karelia 
Central Hospital in 1993. The cost of a visit to the lung 
clinic was FIM 773 including the lung function measure- 
ments (&l sterling=approx. FIM 8) that of an inpatient 
day FIM 1200 and the cost of a visit to the emergency clinic 
FIM 1200. These prices include all cost items (labour, 
capital, maintenance etc.) and the average secretarial work 
needed for each visit. Visits to public health centres were 
valued at the mean cost of such visits in Finland (FIM 178). 
Any extra drugs used (oral corticosteroids and antibiotics) 
were valued at average retail prices. The educating nurse 
used on average 1.5 h per patient for education and arrang- 
ing appointments. The time used by the nurses and physio- 
therapist was valued at their gross salary including social 
security contributions, FIM 100 h ~ ‘. The average return 
transportation cost of a central hospital visit was FIM 48 
and that of a health centre visit FIM 24. 
All sickness days, the time required for intervention visits 
including time used for travelling and the average 
time spent on extra health care visits were recorded 
for the calculation of indirect costs. The total working 
time thus lost was valued at the average daily gross wage 
rate in Finland, including social security contributions 
(FIM 711 day ~ ‘). The cost of diagnosis, the visit for 
randomization and the follow-up visit at 12 months 
were not included, since they were the same in both 
groups and do not thus affect the relative costs of the 
alternatives. 
A cost-effectiveness ratio was calculated for both alter- 
natives with effectiveness measured by all outcome vari- 
ables. Similarly incremental cost-effectiveness ratios were 
derived for the intervention with the conventional pro- 
gramme as the comparator. The net monetary benefit from 
the intervention was calculated by subtracting from the 
intervention cost the saving due to the intervention (cost of 
conventional programme minus the extra costs in the 
intervention programme). 
STATISTICAL ANALYSIS 
Apart from airway responsiveness, all other outcome vari- 
ables are reported as mean values with a 95% confidence 
interval. Because of a skewed distribution, geometric mean 
was calculated for airway responsiveness. Differences 
between the groups in all variables at baseline and at 1 yr 
were tested by using one-way analysis of variance 
(ANOVA). Differences in outcome variables between base- 
line and 1 yr follow-up within the groups were tested by 
using a paired t-test. A P-value ~0.05 was considered 
significant. Because of skewed distributions, Mann- 
Whitney U tests were used to compare the differences in 
costs between the groups. The statistical significance of 
differences in cost-effectiveness ratios between the groups 
was not analysed owing to a lack of an applicable test (such 
as the t test). 
Results 
The randomization was successful since there was no sig- 
nificant difference between the groups at baseline in any 
variable. Three patients from the IG dropped out, because 
they did not show up for follow-up visits. In the control 
group one patient died in a traffic accident and another had 
moved. 
Airway responsiveness was tested for 78 patients at 
baseline in the IG. Two were not tested: one was pregnant 
and the other had a common cold during the last 5 weeks. 
In the CG, 72 patients were tested. Ten patients were not 
tested: one was pregnant, seven had a common cold and 
two had acute obstructions. 
All clinical and other outcome variables indicated a 
significant improvement in the IG during the treatment 
(P<O.OOl except in FEV% P<O.OS). Apart from no signifi- 
cant change in lung function variables, the results were 
similar in the CG. At 1 yr the IG showed a better result in 
all outcome variables, but statistically the groups differed 
significantly from each other only in FEV, (Tables 2 and 3). 
The information given by the patients suggests that the 
doses of inhaled corticosteroid used did not differ signifi- 
cantly between the groups. Nedocromil had to be changed 
for five patients owing to worsening asthmatic symptoms. 
Four of those who continued on nedocromil for the whole 
year were from the CG. Only one patient in the IG used 
nedocromil (dose 8 mg) at 1 yr; four CG patients used a 
mean dose of 10.5 mg. 
Airway responsiveness improved by 0.9 step dose in the 
IG and 0.7 step dose in the CG, but there was no signifi- 
cant difference between the groups. A normal value 
>1.6 mg mll ’ for provocative doses of histamine was 
reached by 11 patients (14%) in the IG and by five patients 
(7%) in the CG. 
There was no retirement due to asthma. All use of extra 
health services was due to problems related to asthma, e.g. 
worsening of asthma status. The IG had no inpatient days 
or emergency room visits and recorded 75 sickness days. 
The CG needed 29 health centre and two emergency room 
visits, 19 specialist consultations and 16 inpatient days, and 
recorded 2.5 times more sickness days (190 days) than the 
IG. However, because of a great variance, there was no 
significant difference between the groups in any item of 
extra cost (Table 4). 
The average total time required by the intervention was 
8 h per patient. The total annual cost was FIM 2757 per 
patient in the IG, of which FIM 1978 was due to the 
intervention. In the CG the total cost was FIM 2351 per 
patient. The difference is statistically significant (P=O.OOOO) 
as is the difference in direct costs, whereas the indirect 
costs were nearly significantly lower in the IG (P=O.O67) 
(Table 5). The total average transportation cost because of 
intervention was FIM 216 per patient. 
All cost-effectiveness ratios are in favour of the interven- 
tion regardless of what effectiveness measure is used. The 
positive incremental ratios show that a unit of possible 
extra effectiveness comes at a price. For example, a one 
percentage point improvement in FEV, with the inter- 
vention costs FIM 86 (Table 6). In terms of purely 
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TABLE 3. The mean HRQOL scores at baseline and at 1 yr in the intervention and control groups 
(95% CI in parentheses) 
Intervention group Control group 
At baseline At 1 yr At baseline At 1 yr 
Difference between 
the groups at 1 yr 
P values 
15D 
SGRQ 
total 
SGRQ 
symptom 
SGRQ 
activity 
SGRQ 
impact 
0.89 0.93*** 0.89 0,91*** 0.47 
(0.87-0.91) (0.90-0.94) (0+&0~91) (0.899 0.94) 
26.4 16.5*** 27.9 20.5*** 0.16 
(23.8-30.7) (13.7-20.0) (24.6-31.5) (16424.4) 
57.5 37.8*** 57.8 40.1*** 0.66 
(54.1-62.1) (33.443.0) (53.8-62.8) (34.4- 45.2) 
27.8 18.2*** 28.0 22.4*** 0.22 
(23.8-32.9) (14.1-22.4) (23.3-33.1) (17.1-27.8) 
15.6 8.7*** 18.2 13.1*** 0.08 
(13.1-20.1) (6.3-l 1.8) (14921.4) (9.5- 16.3) 
Significance of the difference between baseline and one year, paired samples t test: ***P<O.OOl. 
HRQOL, health-related quality of life; 15D, the generic HRQOL instrument; SGRQ, the disease- 
specific St George’s Respiratory Questionnaire. 
TABLE 4. The mean extra costs per patient in FIM in the intervention and control groups after the first treatment year (range 
in parentheses) 
Health Specialist Emergency Inpatient Extra Extra Indirect costs 
centre care care care care corticosteroids antibiotics due to sickness days 
Intervention 
(0&::6) (0-;:46) 
0 0 
(220) (Oi220) 
623 
(O-12 087) 
Control 165 
(O-890) (c&9) (Od~OO) (0-1~000) (s2:60) (0:) 
1733 
(O-63 990) 
Difference, P values 0.27 0.45 0.79 0.79 0.20 0.47 0.56 
FIM, Finnish mark (&l sterling approx. FIM 8). 
monetary cost-benefit, the intervention resulted in a 
negative net benefit (loss) of FIM 406 per patient. 
Discussion 
The patients in this study were mild asthmatics (based on 
the FEV, values). Even so, all outcome measures indicated 
a significant improvement in the IG. At 1 yr the IG showed 
a better result that the CG in all outcome variables, but 
statistically the groups differed significantly from each other 
only in FEV,. From a clinical point of view that is 
noteworthy, because it characterizes an improvement in 
bronchial obstruction. 
Nowadays there is a wide consensus over employing an 
early anti-inflammatory regimen in new asthmatics to avoid 
chronic severe asthma with a disabling pulmonary obstruc- 
tion. Our results strengthen that view, stressing the impor- 
tance of guided self-management education in an early 
phase to avoid later obstruction. The better FEV, in the IG 
could be a result of better self-management skills due to 
intervention or effective supervision every third month. 
It is difficult to estimate how much education alone has 
contributed to the results. 
It is difficult to conduct a randomized trial of educational 
programmes, because patients randomized to the control 
group can obtain information about the intervention. Lack 
of blinding is another methodological problem. To mini- 
mize these risks the patients were made aware of the study 
protocol to the extent that there were to be two groups, but 
they did not know the details of the programme in advance. 
The baseline education for self-management was similar for 
all patients and at that stage the attending chest physician 
did not know the result of randomization. The patients 
filled in the HRQOL questionnaires by themselves and the 
clinical measurements were not carried out by the chest 
physician who ran the trial. Therefore lack of blinding 
should not be a major worry. 
The difference in the improvement rate of airway 
hyperreactivity between the groups was not significant. 
Treatment in usual clinical practice, where the patients 
themselves were responsible for buying their drugs, 
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TABLE 5. The mean direct, indirect and total costs per patient in FIM in the intervention and control 
groups during the first treatment year (range in parentheses) 
Direct costs Indirect costs Total costs 
Intervention group* 
Control group 
P values? 
1269 1489 2151 
(1123-2669) (855512 942) (197814 065) 
595 1727 2351 
(O-12 298) (O-64 038) (O- 64 627) 
0~0000 0.067 0~0000 
*Includes intervention costs: direct FIM 1123; indirect FIM 855. 
TMann-Whitney test. 
FIM, Finnish mark (&l sterling approx. FIM 8). The costs of visits for diagnosis, randomization and 
1 yr follow-up and regular drug therapy are not included. 
TABLE 6. The cost-effectiveness ratios in FIM in the 
intervention and control groups and the incremental 
cost-effectiveness ratios for intervention with different 
effectiveness measures 
Incremental 
cost-effectiveness 
ratio for 
Intervention Control intervention 
15D 
SGRQ total 
FVC 
FEV, 
I’D,, 
(in dose step) 
689 1176 203 
278 318 162 
541 1069 140 
417 1237 86 
3169 3617 1845 
PEF 373 635 110 
decreased airway responsiveness less than reported by 
Juniper et al. in a double-blind randomized study. In it 16 
adult mild asthmatics were treated with 0.4 mg budesonide 
for 1 yr and five patients returned to a normal level of 
airway responsiveness (25). The patients of this study 
attained the same improvement rate as the 58 children 
treated with 0.2 mg budesonide, t.i.d., by Van Essen- 
Zandvliet et al. When evaluated at 8 months, seven patients 
(12%) were in remission (26). 
The disease-specific and generic HRQOL scores 
improved significantly in both groups, but there was no 
significant difference between the groups. The clinical 
importance of these HRQOL changes and their relationship 
to clinical parameters are not yet known and need to be 
further explored. 
The costs of extra health services in the CG varied from 
zero to FIM 64 627 with a mean of FIM 2351. These costs 
per patient in that group were higher than the intervention 
costs alone. After randomization the CG had the next 
planned visit in 11 months time, which can partly explain 
the need for extra health services. The IG, however, had a 
visit to the clinic every third month. Their cost of extra 
health services was only 33% of that in the CG, varying 
from zero to FIM 12 087. 
All cost-effectiveness ratios were in favour of the inter- 
vention regardless of what effectiveness measure is used in 
spite of the fact that the total costs were significantly higher 
in the intervention group. However, since there was no 
statistically significant difference between the groups in any 
effectiveness variable except FEV, and there was a signifi- 
cant difference in total costs in favour of the conventional 
programme, it cannot be unambiguously concluded that the 
intervention was more cost effective than the conventional 
programme. Rather, the significances suggest the contrary, 
reducing the cost-effectiveness analysis to a cost- 
minimization study. However, the fact that at 1 yr the IG 
showed a consistently better, but not statistically signifi- 
cantly better, result in all outcome variables might be 
indicative of a true difference, but the sample sizes are too 
small to substantiate it. 
The incremental cost-effectiveness ratios show the extra 
cost per unit of extra effectiveness that the intervention 
produces over the conventional programme. The fact that 
all incremental ratios are positive suggests that a unit of 
possible extra effectiveness in the intervention programme 
comes at an extra cost and that the conventional pro- 
gramme dominates the intensive one regardless of the 
effectiveness measure. The smallest extra cost (FIM 86) 
occurs when effectiveness was measured by FEV,. It was 
also the only effectiveness variable in terms of which the 
groups differed significantly. Also, a purely monetary cost- 
benefit calculation showed that the intervention resulted in 
a negative net benefit (loss) of FIM 406 per patient. 
However, viewed in another way, at an extra cost of FIM 
406 the intervention produced a significant improvement in 
FEV,. Whether the difference is clinically so significant that 
is justifies the extra cost is for the doctors to decide. 
Actually it is not known what constitutes a clinically 
relevant improvement in FEV, among new mild asthmatics. 
FitzGerald (27) Bosley et al. (28) and Kolbe et al. (29) 
emphasize that asthma education should be more individu- 
alized and better directed because of many behavioural and 
psychosocial barriers. Therefore it would be important to 
be able to identify at baseline which patients may not 
benefit from a conventional education programme, but 
might benefit from an intensive one. Moreover, a 1 yr 
follow-up may be too short a period for drawing firm 
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conclusions about the cost-effectiveness of an intensive 
education programme for a chronic condition. 
In conclusion, in 1 yr follow-up the intensive patient 
education for the self-management of newly diagnosed mild 
asthmatics produced a significantly better outcome than the 
conventional programme only in terms of FEV,. When 
effectiveness was measured by HRQOL scores, there was no 
significant difference between the programmes. The inter- 
vention was not superior to the conventional programme in 
terms of either cost-effectiveness or monetary net benefit. A 
longer follow-up of mild asthmatics may be needed before 
definitive conclusions about the cost-effectiveness of this 
kind of intervention can be drawn. 
Acknowledgements 14. 
This work was supported by The Finnish Office for Health 
Care Technology Assessment and Viipuri Tuberculosis 
Foundation. We would like to thank Vesa Vilkka, MD, 
for the statistical analysis, Markku Pekurinen, PhD, 
for helping in HRQOL measurements, and the staff of 
the Lung and Clinical Physiology Departments in the 
South Karelia Central Hospital for assistance in the clinical 
work. 
References 18. 
1. 
2. 
3. 
4. 
5. 
6. 
Ministry of Social Affairs and Health. Asthma pro- 
gramme in Finland 19942004. Working group report. 
Clin Exp Allergy 1996; 26 (Suppl.): 11-24. 
Worth H. Patient education in asthmatic adults. Lung 
1990; 168 (Suppl): 463468. 
Bailey WC, Richards JM, Brooks CM, Soong SJ, 
Windsor RA, Manzella BA. A randomized trial to 
improve self-management practices of adults with 
asthma. Arch Intern A4ed 1990; 150: 16641668. 
Miihlhauser I, Richter B, Kraut D, Weske G, Worth H, 
Berger M. Evaluation of a structured treatment and 
teaching programme on asthma. J Intern Med 1991; 
230: 157-164. 
Mayo PH, Richman J, Harris HW. Results of a pro- 
gram to reduce admissions for adult asthma. Ann Intern 
Med 1990; 112: 864871. 
Allen RM, Jones MP. Oldenburg B. Randomised trial 
of an asthma self-management programme for adults. 
Thorax 1995; 50: 731-738. 
Boulet LP, Boutin H, Cote J, Leblanc P, Laviolette M. 
Evaluation of an asthma self-management education 
program. J Asthma 1995; 32: 199-206. 
Windsor RA, Bailey WC, Richards JM Jr, Manzella B, 
Soong S-J, Brooks M. Evaluation of the efficacy and 
cost effectiveness of health education methods to 
increase medication adherence among adults with 
asthma. Am J Public Health 1990; 80: 1519-1521. 
Bolton MB, Tilley BC, Kuder J, Reeves T, Schultz ZR. 
The cost and effectiveness of an education program for 
adults who have asthma. J Gen Intern Med 1991; 6: 
401407. 
10. 
11. 
12. 
13. 
15. 
16. 
17. 
19. 
20. 
21. 
22. 
23. 
24. 
25. 
Sondergaard B, Davidsen F, Kirkeby B, Rasmussen M, 
Hey H. The economics of an intensive education 
programme for asthmatic patients. A prospective 
controlled trial. Pharmacoeconomics 1992; 1: 207-212. 
Trautner C, Richter B, Berger M. Cost-effectivess of a 
structured treatment and teaching programme on 
asthma. Eur Respir J 1993; 6: 1485-1491. 
Taitel HS, Kotses H, Bernstein IL, Creer TL. A 
self-management program for adult asthma. Part II: 
cost-benefit analysis. J Allergy Clin Zmmunol 1995; 95: 
672-676. 
Lahdensuo A, Haahtela T, Herrala J et al. Randomised 
comparison of guided self-management and traditional 
treatment of asthma over one year. Br Med J 1996; 312: 
748-752. 
Neri M, Migliori GB, Spanevello A et al. Economic 
analysis of two structured treatment and teaching 
programs on asthma. Allergy 1996; 51: 313-319. 
American Thoracic Society. Guidelines to the diagnosis 
and treatment of asthma. Am Rev Respir Dis 1987; 136: 
225-244. 
Viljanen AA, Halttunen PK, Kreus K-E, Viljanen BC 
Spirometric studies in nonsmoking, healthy adults. 
Stand J Clin Lab Invest 1982; 42 (Suppl 159): S-20. 
Nunn AJ, Gregg I. New regression equations for 
predicting peak flow in adults. Br Med J 1989; 298: 
1068-1070. 
Sovijarvi ARA, Malmberg LM, Reinikainen K, RytiilH 
P, Poppius HA. Rapid dosimetric method with con- 
trolled tidal breathing for histamine challenge. Chest 
1993; 104: 164170. 
Sintonen H, Pekurinen M. A fifteen-dimensional 
measure of life (15D) and its applications. In: Walker 
SP, Rosser RM, eds. Quality of Life Assessment: 
Key Issues in the 1990s. Dordrecht: Kluwer, 1993; 
pp. 185-195. 
Sintonen H, Pekurinen M. A generic 15-dimensional 
measure of health-related quality of life (15D). J Sot 
Med 1989; 26: 85-96. 
Rissanen P, Sintonen H, Pekurinen M. 15D terveyteen 
liittyvan ellmanlaatumittarin, visuaalisen analo- 
giamitta rin ja koetun terveydentilan mittarin arvot 
aikuisikaisessl normaalivlestiissa. J Sot Med 1995; 32: 
207-2 11. 
Jones PW, Quirk F, Baveystock C. The St George’s 
Respiratory Questionnaire. Respir Med 1991; 85 
(Suppl. B): 25-3 1. 
Quirk F, Baveystock C, Wilson R, Jones P. Influence of 
demographic and disease related factors on the degree 
of distress associated with symptoms and restrictions 
on daily living due to asthma in six countries. Eur 
Respir J 1991: 4: 167-171. 
Jones PW, Quirk F, Baveystock C, Littlejohns P. A 
self-complete measure of health status for chronic 
airflow limitation, The St. George’s Respiratory 
Questionnaire. Am Rev Respir Dis 1992; 145: 1321- 
1327. 
Juniper EF, Kline PA, Vanzieleghem A, Ramsdale EH, 
O’Byrne PM, Hargreave FE. Effect of long-term treat- 
ment with an inhaled corticosteroid (budesonide) on 
SELF-MANAGEMENT 0~ ASTHMATIC PATIENTS 307 
airway hyperresponsiveness and clinical asthma in non- 
steroid-dependent asthmatics. Am Rev Respir Dis 1990; 
143: 832-836. 
26. Van Essen-Zandvliet EE, Hughes MD, Waalkens HJ, 
Duiverman EJ, Kerrebijn KF, Dutch CNSLD Study 
Group. Remission of childhood asthma after long-term 
treatment with an inhaled corticosteroid (budesonide): 
can it be achieved? Eur Respir J 1994; 7: 63-68. 
27. FitzGerald J. Psychosocial barriers to asthma educa- 
tion. Chest 1994; 106: 26OS-263s. 
28. Bosley CM, Fosbury JA, Cochrane GM. The psycho- 
logical factors associated with poor compliance with 
treatment in asthma. Eur Respir J 1995; 8: 8999904. 
29. Kolbe J, Vamos M, James F, Elkind G, Garrett J. 
Assessment of practical knowledge of self-management 
of acute asthma. Chest 1996; 109: 86-90. 
